QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bristol-myers-squibb-and-insitro--announced-the-next-phase-of-their-collaboration-to-discover-new-molecules-with-potential-as-new-treatments-for-amyotrophic-lateral-sclerosis-collaboration-extension-builds-on-5-year-agreement-announced-in-2020

insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE:BMY), today announ...

 bristol-myers-squibb-to-present-data-from-over-50-oncology-studies-at-esmo-congress-2025-covering-over-10-cancer-types-across-pipeline-and-portfolio

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the Euro...

 systimmune-announced-first-patient-dosed-in-ph23-izabright-breast01-trial-of-iza-bren-in-previously-untreated-triple-negative-breast-cancer-250m-milestone-payment-triggered-from-bristol-myers-squibb

SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-B...

 bristol-myers-expands-cell-therapy-portfolio-with-orbital-therapeutics-acquisition

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portf...

 bristol-myers-squibb-agreed-to-acquire-orbital-therapeutics-a-privately-held-biotechnology-for-15b

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with po...

 these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

 health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

 trumps-100-drug-tariffs-a-meaningful-commercial-hit-for-americans-but-loopholes-could-blunt-impact-says-analyst

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks t...

 trumps-100-pharmaceutical-tariff-the-270-billion-manufacturing-war-that-could-reshape-your-medicine-cabinet

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creatin...

 bristol-myers-to-sell-its-pill-for-psoriasis-directly-to-cash-paying-patients--at-80-discount-to-the-drugs-list-price-following-president-donald-trumps-demand

https://www.bloomberg.com/news/articles/2025-09-25/bristol-to-sell-psoriasis-pill-for-80-off-after-trump-demand

 bristol-myers-squibb-franchise-gains-momentum-with-phase-3-results-in-multiple-myeloma-patients

Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to futur...

 bristol-myers-plans-uk-launch-of-schizophrenia-drug-cobenfy-matching-us-price--reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-plans-launch-schizophrenia-drug-uk-list-price-equal-u...

Core News & Articles

For next-generation CRM with deep, industry-specific AI agentsPLEASANTON, Calif., Sept. 22, 2025 /PRNewswire/ -- Veeva Systems ...

 johnson--johnson-protagonist-study-shows-superior-skin-clearance-in-psoriasis-trials

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION